

KRAS2 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP16005b**Specification**

KRAS2 Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [P01116](#)**KRAS2 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 3845**Other Names**

GTPase KRas, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, N-terminally processed, KRAS, KRAS2, RASK2

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

KRAS2 Antibody (C-term) Blocking Peptide - Protein Information**Name** KRAS**Synonyms** KRAS2, RASK2**Function**

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621, PubMed:39809765). Plays an important role in the regulation of cell proliferation (PubMed:22711838, PubMed:23698361). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306).

Cellular Location

Cell membrane; Lipid-anchor; Cytoplasmic side. Endomembrane system. Cytoplasm, cytosol

KRAS2 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

KRAS2 Antibody (C-term) Blocking Peptide - Images

KRAS2 Antibody (C-term) Blocking Peptide - Background

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.

KRAS2 Antibody (C-term) Blocking Peptide - References

Bruckman, K.C., et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
110(5):632-637(2010) Wong, K.K., et al. Am. J. Pathol. 177(4):1611-1617(2010) Irahara, N., et al.
Diagn. Mol. Pathol. 19(3):157-163(2010) Carotenuto, P., et al. Pharmacogenomics
11(8):1169-1179(2010) Leventopoulos, G., et al. Clin. Exp. Rheumatol. 28(4):556-557(2010)